Study for people with Lung Cancer

Recruiting Not a phased study

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Not a phased study
Sponsor University of Sydney
Registry number NCT04086082
Started 24 May 2023 Today 16 October 2026 Estimated completion 1 December 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Alfred Health Melbourne VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 30

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Is willing to comply with all trial procedures and intends to provide written Informed Consent for participation in this trial.

* Patients undergoing external beam radiotherapy.

* Histologically proven Stage I NSCLC or oligometastatic lung metastases (3 or less).

* MRI/4D-CT prior to insertion of fiducial markers.

* Patient must be able to have fiducial markers placed in the lung (if on anticoagulants, must be cleared by LMO or cardiologist).

* ECOG performance status 0-2.

* A maximum of three metastases to the lung from any non-haematological malignancy. Multiple metastases will be treated separately.

* 1 cm ≤ Tumour diameter in any dimension ≤ = 5 cm.

* The distance between the tumour centroid and the top end of the diaphragm is \<=10 cm.

Exclusion Criteria:

* Patient has low respiratory performance as evaluated by the physicians.

* Previous high-dose thoracic radiotherapy.

* Less than one fiducial marker implanted in the lung.

* Fiducial markers are too far from the tumour centroid (\>9 cm).

* Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Hormonal manipulation agents are allowable (e.g. aromatase inhibitors, selective oestrogen receptor modulators, and gonadotropin releasing hormone receptor modulators).

* Targeted agents (such as sunitinib, bevacizumab and tarceva) within 7 days of commencement of treatment, or concurrently with treatment.

* Women who are pregnant or lactating.

* Unwilling or unable to complete quality of life questionnaires.

Dates on the record

Started 24 May 2023
Estimated completion 1 December 2028
Registry last updated 20 May 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 20 May 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.